| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | IgG receptor activity | 6.85e-10 | 7 | 162 | 5 | GO:0019770 | |
| GeneOntologyMolecularFunction | immunoglobulin receptor activity | 7.40e-10 | 14 | 162 | 6 | GO:0019763 | |
| GeneOntologyMolecularFunction | IgG binding | 1.47e-08 | 11 | 162 | 5 | GO:0019864 | |
| GeneOntologyMolecularFunction | immunoglobulin binding | 1.02e-05 | 36 | 162 | 5 | GO:0019865 | |
| GeneOntologyMolecularFunction | high-affinity IgG receptor activity | 6.54e-05 | 2 | 162 | 2 | GO:0019771 | |
| GeneOntologyMolecularFunction | leukotriene receptor binding | 6.54e-05 | 2 | 162 | 2 | GO:0031774 | |
| GeneOntologyMolecularFunction | 5-methylcytosine dioxygenase activity | 1.95e-04 | 3 | 162 | 2 | GO:0070579 | |
| GeneOntologyMolecularFunction | low-affinity IgG receptor activity | 3.88e-04 | 4 | 162 | 2 | GO:0019772 | |
| GeneOntologyMolecularFunction | ubiquitin-like protein-specific endopeptidase activity | 6.44e-04 | 5 | 162 | 2 | GO:0070137 | |
| GeneOntologyMolecularFunction | SUMO-specific endopeptidase activity | 6.44e-04 | 5 | 162 | 2 | GO:0070139 | |
| GeneOntologyBiologicalProcess | antibody-dependent cellular cytotoxicity | 3.33e-08 | 13 | 161 | 5 | GO:0001788 | |
| GeneOntologyBiologicalProcess | type IIa hypersensitivity | 7.68e-08 | 15 | 161 | 5 | GO:0001794 | |
| GeneOntologyBiologicalProcess | type II hypersensitivity | 7.68e-08 | 15 | 161 | 5 | GO:0002445 | |
| GeneOntologyBiologicalProcess | Fc receptor signaling pathway | 5.31e-07 | 62 | 161 | 7 | GO:0038093 | |
| GeneOntologyBiologicalProcess | Fc-gamma receptor signaling pathway | 5.43e-07 | 39 | 161 | 6 | GO:0038094 | |
| GeneOntologyBiologicalProcess | regulation of type IIa hypersensitivity | 1.13e-06 | 11 | 161 | 4 | GO:0001796 | |
| GeneOntologyBiologicalProcess | regulation of type II hypersensitivity | 1.13e-06 | 11 | 161 | 4 | GO:0002892 | |
| GeneOntologyBiologicalProcess | hypersensitivity | 1.28e-06 | 25 | 161 | 5 | GO:0002524 | |
| GeneOntologyBiologicalProcess | type III hypersensitivity | 4.61e-06 | 5 | 161 | 3 | GO:0001802 | |
| GeneOntologyBiologicalProcess | regulation of type III hypersensitivity | 4.61e-06 | 5 | 161 | 3 | GO:0001803 | |
| GeneOntologyBiologicalProcess | positive regulation of type III hypersensitivity | 4.61e-06 | 5 | 161 | 3 | GO:0001805 | |
| GeneOntologyBiologicalProcess | regulation of hypersensitivity | 1.27e-05 | 19 | 161 | 4 | GO:0002883 | |
| GeneOntologyBiologicalProcess | acute inflammatory response to antigenic stimulus | 1.83e-05 | 42 | 161 | 5 | GO:0002438 | |
| GeneOntologyBiologicalProcess | positive regulation of type IIa hypersensitivity | 5.38e-05 | 10 | 161 | 3 | GO:0001798 | |
| GeneOntologyBiologicalProcess | positive regulation of type II hypersensitivity | 5.38e-05 | 10 | 161 | 3 | GO:0002894 | |
| GeneOntologyBiologicalProcess | regulation of acute inflammatory response to antigenic stimulus | 5.46e-05 | 27 | 161 | 4 | GO:0002864 | |
| GeneOntologyBiologicalProcess | negative regulation of type I hypersensitivity | 6.06e-05 | 2 | 161 | 2 | GO:0001811 | |
| GeneOntologyBiologicalProcess | positive regulation of hypersensitivity | 1.98e-04 | 15 | 161 | 3 | GO:0002885 | |
| GeneOntologyBiologicalProcess | endocytosis | RABEPK DNAJC13 BMP2K PSG2 ABCA13 PSG11 ICAM3 CKAP5 PLA2R1 FCGR2C FCGR1A FCGR1BP FCGR2A FCGR2B TLR2 PRKCD LY75 | 2.63e-04 | 827 | 161 | 17 | GO:0006897 |
| GeneOntologyBiologicalProcess | response to peptidoglycan | 2.93e-04 | 17 | 161 | 3 | GO:0032494 | |
| GeneOntologyBiologicalProcess | positive regulation of acute inflammatory response to antigenic stimulus | 2.93e-04 | 17 | 161 | 3 | GO:0002866 | |
| GeneOntologyBiologicalProcess | receptor-mediated endocytosis | RABEPK DNAJC13 BMP2K PSG2 PSG11 PLA2R1 FCGR1A FCGR1BP FCGR2A FCGR2B | 3.26e-04 | 337 | 161 | 10 | GO:0006898 |
| GeneOntologyBiologicalProcess | antigen processing and presentation of exogenous peptide antigen via MHC class I | 3.49e-04 | 18 | 161 | 3 | GO:0042590 | |
| GeneOntologyBiologicalProcess | negative regulation of hypersensitivity | 3.60e-04 | 4 | 161 | 2 | GO:0002884 | |
| GeneOntologyCellularComponent | NSL complex | 7.34e-05 | 11 | 163 | 3 | GO:0044545 | |
| MousePheno | abnormal B cell apoptosis | 3.44e-06 | 47 | 124 | 6 | MP:0008781 | |
| MousePheno | decreased susceptibility to autoimmune hemolytic anemia | 6.73e-06 | 5 | 124 | 3 | MP:0004828 | |
| MousePheno | abnormal pancreas physiology | PCSK2 PSG2 PSG11 SLC39A8 FCGR2A MTUS1 FCGR2B TLR2 PRKCD EIF2AK3 PDZD2 | 5.71e-05 | 292 | 124 | 11 | MP:0002693 |
| MousePheno | increased tumor incidence | PCSK2 RANBP2 RARRES1 PSG2 PSG11 TSC1 FLVCR2 CHORDC1 CABLES1 BLM MSH6 PLA2R1 MTUS1 TLR2 TET1 | 6.97e-05 | 530 | 124 | 15 | MP:0002020 |
| MousePheno | abnormal insulin secretion | 1.41e-04 | 171 | 124 | 8 | MP:0003564 | |
| MousePheno | increased classified tumor incidence | PCSK2 RANBP2 RARRES1 TSC1 FLVCR2 CHORDC1 CABLES1 BLM MSH6 MTUS1 TLR2 TET1 | 1.44e-04 | 381 | 124 | 12 | MP:0010273 |
| MousePheno | abnormal classified tumor incidence | PCSK2 RANBP2 RARRES1 TSC1 FLVCR2 CHORDC1 CABLES1 BLM MSH6 MTUS1 TLR2 TET1 | 1.55e-04 | 384 | 124 | 12 | MP:0020188 |
| MousePheno | hunched posture | 1.55e-04 | 91 | 124 | 6 | MP:0001505 | |
| MousePheno | abnormal endocrine pancreas secretion | 1.71e-04 | 176 | 124 | 8 | MP:0014195 | |
| MousePheno | increased uterus tumor incidence | 1.83e-04 | 13 | 124 | 3 | MP:0009222 | |
| MousePheno | abnormal pancreas secretion | 2.24e-04 | 183 | 124 | 8 | MP:0002694 | |
| MousePheno | decreased B cell apoptosis | 2.31e-04 | 14 | 124 | 3 | MP:0008783 | |
| MousePheno | increased anti-chromatin antibody level | 2.31e-04 | 14 | 124 | 3 | MP:0004829 | |
| MousePheno | increased insulin secretion | 2.54e-04 | 64 | 124 | 5 | MP:0003058 | |
| Domain | Ig_2 | 4.09e-05 | 73 | 162 | 6 | PF13895 | |
| Domain | ig | MYOM1 PSG2 PSG11 ICAM3 IL1RAPL1 FCGR1A FCGR1BP FCGR2A FCGR2B | 4.28e-05 | 190 | 162 | 9 | PF00047 |
| Domain | Immunoglobulin | MYOM1 PSG2 PSG11 ICAM3 IL1RAPL1 FCGR1A FCGR1BP FCGR2A FCGR2B | 4.28e-05 | 190 | 162 | 9 | IPR013151 |
| Domain | HECW_N | 7.48e-05 | 2 | 162 | 2 | IPR032348 | |
| Domain | CABLES1/2 | 7.48e-05 | 2 | 162 | 2 | IPR012388 | |
| Domain | HECW_N | 7.48e-05 | 2 | 162 | 2 | PF16562 | |
| Domain | CHROMO_1 | 9.49e-05 | 28 | 162 | 4 | PS00598 | |
| Domain | CHROMO_2 | 9.49e-05 | 28 | 162 | 4 | PS50013 | |
| Domain | Kringle-like | 1.62e-04 | 32 | 162 | 4 | IPR013806 | |
| Domain | Chromodomain-like | 1.62e-04 | 32 | 162 | 4 | IPR016197 | |
| Domain | Chromo/shadow_dom | 1.83e-04 | 33 | 162 | 4 | IPR000953 | |
| Domain | CHROMO | 1.83e-04 | 33 | 162 | 4 | SM00298 | |
| Domain | CHD_N | 2.23e-04 | 3 | 162 | 2 | IPR012958 | |
| Domain | CHD_C2 | 2.23e-04 | 3 | 162 | 2 | IPR012957 | |
| Domain | CHDCT2 | 2.23e-04 | 3 | 162 | 2 | PF08074 | |
| Domain | CHDNT | 2.23e-04 | 3 | 162 | 2 | PF08073 | |
| Domain | DUF1086 | 2.23e-04 | 3 | 162 | 2 | IPR009462 | |
| Domain | DUF1087 | 2.23e-04 | 3 | 162 | 2 | IPR009463 | |
| Domain | DUF1087 | 2.23e-04 | 3 | 162 | 2 | PF06465 | |
| Domain | DUF1086 | 2.23e-04 | 3 | 162 | 2 | PF06461 | |
| Domain | DUF1087 | 2.23e-04 | 3 | 162 | 2 | SM01147 | |
| Domain | DUF1086 | 2.23e-04 | 3 | 162 | 2 | SM01146 | |
| Domain | DNA/RNA_helicase_DEAH_CS | 2.32e-04 | 35 | 162 | 4 | IPR002464 | |
| Domain | DEAH_ATP_HELICASE | 3.20e-04 | 38 | 162 | 4 | PS00690 | |
| Domain | TUDOR | 9.99e-04 | 23 | 162 | 3 | PS50304 | |
| Domain | IGc2 | 1.05e-03 | 235 | 162 | 8 | SM00408 | |
| Domain | Ig_sub2 | 1.05e-03 | 235 | 162 | 8 | IPR003598 | |
| Domain | FAST_2 | 1.10e-03 | 6 | 162 | 2 | PF08368 | |
| Domain | RAP | 1.10e-03 | 6 | 162 | 2 | SM00952 | |
| Domain | RAP | 1.10e-03 | 6 | 162 | 2 | PF08373 | |
| Domain | RAP | 1.10e-03 | 6 | 162 | 2 | PS51286 | |
| Domain | FAST_1 | 1.10e-03 | 6 | 162 | 2 | PF06743 | |
| Domain | - | 1.10e-03 | 6 | 162 | 2 | 2.140.10.10 | |
| Domain | FAST_Leu-rich | 1.10e-03 | 6 | 162 | 2 | IPR010622 | |
| Domain | Quinoprotein_ADH-like_fam | 1.10e-03 | 6 | 162 | 2 | IPR027295 | |
| Domain | WxxW_domain | 1.10e-03 | 6 | 162 | 2 | IPR025155 | |
| Domain | Mucin2_WxxW | 1.10e-03 | 6 | 162 | 2 | PF13330 | |
| Domain | FAST_2 | 1.10e-03 | 6 | 162 | 2 | IPR013579 | |
| Domain | RAP | 1.10e-03 | 6 | 162 | 2 | IPR013584 | |
| Domain | Chromo_domain | 1.13e-03 | 24 | 162 | 3 | IPR023780 | |
| Domain | Chromo | 1.44e-03 | 26 | 162 | 3 | PF00385 | |
| Domain | Trimer_CC | 1.53e-03 | 7 | 162 | 2 | IPR015049 | |
| Domain | DUF1899 | 1.53e-03 | 7 | 162 | 2 | IPR015048 | |
| Domain | Mob1_phocein | 1.53e-03 | 7 | 162 | 2 | PF03637 | |
| Domain | Trimer_CC | 1.53e-03 | 7 | 162 | 2 | PF08954 | |
| Domain | DUF1899 | 1.53e-03 | 7 | 162 | 2 | PF08953 | |
| Domain | Peptidase_C48_C | 1.53e-03 | 7 | 162 | 2 | IPR003653 | |
| Domain | Coronin | 1.53e-03 | 7 | 162 | 2 | IPR015505 | |
| Domain | Peptidase_C48 | 1.53e-03 | 7 | 162 | 2 | PF02902 | |
| Domain | MOB_kinase_act_fam | 1.53e-03 | 7 | 162 | 2 | IPR005301 | |
| Domain | DUF1899 | 1.53e-03 | 7 | 162 | 2 | SM01166 | |
| Domain | - | 1.53e-03 | 7 | 162 | 2 | 1.20.140.30 | |
| Domain | Mob1_phocein | 1.53e-03 | 7 | 162 | 2 | SM01388 | |
| Domain | ULP_PROTEASE | 1.53e-03 | 7 | 162 | 2 | PS50600 | |
| Domain | HECT | 1.61e-03 | 27 | 162 | 3 | PF00632 | |
| Domain | HECTc | 1.61e-03 | 27 | 162 | 3 | SM00119 | |
| Domain | TUDOR | 1.61e-03 | 27 | 162 | 3 | SM00333 | |
| Domain | HECT_dom | 1.61e-03 | 27 | 162 | 3 | IPR000569 | |
| Domain | HECT | 1.61e-03 | 27 | 162 | 3 | PS50237 | |
| Domain | ADH_Zn_CS | 2.02e-03 | 8 | 162 | 2 | IPR002328 | |
| Domain | ADH_ZINC | 2.02e-03 | 8 | 162 | 2 | PS00059 | |
| Domain | Tudor | 2.19e-03 | 30 | 162 | 3 | IPR002999 | |
| Domain | Zinc_finger_PHD-type_CS | 2.45e-03 | 65 | 162 | 4 | IPR019786 | |
| Domain | SNF2_N | 2.64e-03 | 32 | 162 | 3 | IPR000330 | |
| Domain | SNF2_N | 2.64e-03 | 32 | 162 | 3 | PF00176 | |
| Domain | LIM | 3.04e-03 | 69 | 162 | 4 | PF00412 | |
| Domain | - | 3.21e-03 | 70 | 162 | 4 | 2.10.110.10 | |
| Domain | LIM | 3.37e-03 | 71 | 162 | 4 | SM00132 | |
| Domain | Znf_LIM | 3.37e-03 | 71 | 162 | 4 | IPR001781 | |
| Domain | LIM_DOMAIN_1 | 3.37e-03 | 71 | 162 | 4 | PS00478 | |
| Domain | LIM_DOMAIN_2 | 3.37e-03 | 71 | 162 | 4 | PS50023 | |
| Domain | IG | MYOM1 PSG2 PSG11 ICAM3 CD200R1 IL1RAPL1 FCGR1A FCGR1BP FCGR2A FCGR2B | 3.78e-03 | 421 | 162 | 10 | SM00409 |
| Domain | Ig_sub | MYOM1 PSG2 PSG11 ICAM3 CD200R1 IL1RAPL1 FCGR1A FCGR1BP FCGR2A FCGR2B | 3.78e-03 | 421 | 162 | 10 | IPR003599 |
| Domain | WD40_repeat_dom | 4.46e-03 | 297 | 162 | 8 | IPR017986 | |
| Domain | THAP | 4.66e-03 | 12 | 162 | 2 | SM00980 | |
| Domain | THAP | 4.66e-03 | 12 | 162 | 2 | PF05485 | |
| Domain | ZF_THAP | 4.66e-03 | 12 | 162 | 2 | PS50950 | |
| Domain | DM3 | 4.66e-03 | 12 | 162 | 2 | SM00692 | |
| Domain | Znf_C2CH | 4.66e-03 | 12 | 162 | 2 | IPR006612 | |
| Domain | FA | 5.48e-03 | 13 | 162 | 2 | PF08736 | |
| Domain | FERM-adjacent | 5.48e-03 | 13 | 162 | 2 | IPR014847 | |
| Domain | FA | 5.48e-03 | 13 | 162 | 2 | SM01195 | |
| Domain | FN_type2_col-bd | 6.35e-03 | 14 | 162 | 2 | IPR000562 | |
| Domain | FN2_2 | 6.35e-03 | 14 | 162 | 2 | PS51092 | |
| Domain | FN2_1 | 6.35e-03 | 14 | 162 | 2 | PS00023 | |
| Domain | TUDOR | 6.35e-03 | 14 | 162 | 2 | PF00567 | |
| Domain | fn2 | 6.35e-03 | 14 | 162 | 2 | PF00040 | |
| Domain | FN2 | 6.35e-03 | 14 | 162 | 2 | SM00059 | |
| Domain | C2 | 6.89e-03 | 137 | 162 | 5 | SM00239 | |
| Domain | WD40 | 7.53e-03 | 259 | 162 | 7 | PF00400 | |
| Domain | WW | 7.86e-03 | 47 | 162 | 3 | PF00397 | |
| Domain | C2 | 7.98e-03 | 142 | 162 | 5 | PS50004 | |
| Domain | PKS_ER | 8.28e-03 | 16 | 162 | 2 | IPR020843 | |
| Domain | ADH_N | 8.28e-03 | 16 | 162 | 2 | PF08240 | |
| Domain | PKS_ER | 8.28e-03 | 16 | 162 | 2 | SM00829 | |
| Domain | ADH_N | 8.28e-03 | 16 | 162 | 2 | IPR013154 | |
| Domain | WW | 8.33e-03 | 48 | 162 | 3 | SM00456 | |
| Domain | HEAT | 8.33e-03 | 48 | 162 | 3 | PF02985 | |
| Pubmed | 5.13e-10 | 4 | 167 | 4 | 9551950 | ||
| Pubmed | 5.13e-10 | 4 | 167 | 4 | 31562320 | ||
| Pubmed | Fc receptor regulation of protective immunity against Chlamydia trachomatis. | 5.13e-10 | 4 | 167 | 4 | 11872097 | |
| Pubmed | 5.13e-10 | 4 | 167 | 4 | 9490697 | ||
| Pubmed | 5.13e-10 | 4 | 167 | 4 | 28028748 | ||
| Pubmed | Fc receptor-mediated antibody regulation of T cell immunity against intracellular pathogens. | 5.13e-10 | 4 | 167 | 4 | 12898452 | |
| Pubmed | Fcgamma receptor cross-linking stimulates cell proliferation of macrophages via the ERK pathway. | 5.13e-10 | 4 | 167 | 4 | 19996316 | |
| Pubmed | Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. | 5.13e-10 | 4 | 167 | 4 | 16585547 | |
| Pubmed | The mouse Fc receptor for IgG (Ly-17): molecular cloning and specificity. | 5.13e-10 | 4 | 167 | 4 | 2957319 | |
| Pubmed | 5.13e-10 | 4 | 167 | 4 | 12528127 | ||
| Pubmed | Dynamic macrophage "probing" is required for the efficient capture of phagocytic targets. | 5.13e-10 | 4 | 167 | 4 | 21135140 | |
| Pubmed | Destructive arthritis in the absence of both FcgammaRI and FcgammaRIII. | 2.55e-09 | 5 | 167 | 4 | 18354234 | |
| Pubmed | Mouse model recapitulating human Fcγ receptor structural and functional diversity. | 2.55e-09 | 5 | 167 | 4 | 22474370 | |
| Pubmed | Reversal of proinflammatory responses by ligating the macrophage Fcgamma receptor type I. | 2.55e-09 | 5 | 167 | 4 | 9653099 | |
| Pubmed | 2.55e-09 | 5 | 167 | 4 | 9200458 | ||
| Pubmed | Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptor-deficient mice. | 2.55e-09 | 5 | 167 | 4 | 10051626 | |
| Pubmed | C-reactive protein binding to murine leukocytes requires Fc gamma receptors. | 2.55e-09 | 5 | 167 | 4 | 10640769 | |
| Pubmed | 2.55e-09 | 5 | 167 | 4 | 16520392 | ||
| Pubmed | Role of FcRs in animal model of autoimmune bullous pemphigoid. | 2.55e-09 | 5 | 167 | 4 | 16920981 | |
| Pubmed | 2.55e-09 | 5 | 167 | 4 | 9143687 | ||
| Pubmed | 2.55e-09 | 5 | 167 | 4 | 12421967 | ||
| Pubmed | 2.55e-09 | 5 | 167 | 4 | 2944118 | ||
| Pubmed | 2.55e-09 | 5 | 167 | 4 | 28852207 | ||
| Pubmed | 2.55e-09 | 5 | 167 | 4 | 17328787 | ||
| Pubmed | 2.55e-09 | 5 | 167 | 4 | 27265505 | ||
| Pubmed | Human IgG Fc domain engineering enhances antitoxin neutralizing antibody activity. | 2.55e-09 | 5 | 167 | 4 | 24401277 | |
| Pubmed | Inhibition of murine fibrocyte differentiation by cross-linked IgG is dependent on FcγRI. | 2.55e-09 | 5 | 167 | 4 | 24752483 | |
| Pubmed | 7.63e-09 | 6 | 167 | 4 | 16513171 | ||
| Pubmed | 7.63e-09 | 6 | 167 | 4 | 21832933 | ||
| Pubmed | 7.63e-09 | 6 | 167 | 4 | 21940940 | ||
| Pubmed | 7.63e-09 | 6 | 167 | 4 | 20494341 | ||
| Pubmed | 7.63e-09 | 6 | 167 | 4 | 18495955 | ||
| Pubmed | 7.63e-09 | 6 | 167 | 4 | 19949107 | ||
| Pubmed | 7.63e-09 | 6 | 167 | 4 | 22430937 | ||
| Pubmed | 1.77e-08 | 7 | 167 | 4 | 16418399 | ||
| Pubmed | 1.77e-08 | 7 | 167 | 4 | 26216934 | ||
| Pubmed | 1.77e-08 | 7 | 167 | 4 | 15728518 | ||
| Pubmed | 1.77e-08 | 7 | 167 | 4 | 24412922 | ||
| Pubmed | 1.77e-08 | 7 | 167 | 4 | 14764729 | ||
| Pubmed | 1.77e-08 | 7 | 167 | 4 | 18063701 | ||
| Pubmed | IgG-Immune Complexes Promote B Cell Memory by Inducing BAFF. | 1.77e-08 | 7 | 167 | 4 | 26621863 | |
| Pubmed | 1.77e-08 | 7 | 167 | 4 | 12794146 | ||
| Pubmed | FcgammaRIV: a novel FcR with distinct IgG subclass specificity. | 1.77e-08 | 7 | 167 | 4 | 16039578 | |
| Pubmed | 1.77e-08 | 7 | 167 | 4 | 23754379 | ||
| Pubmed | 1.77e-08 | 7 | 167 | 4 | 32195245 | ||
| Pubmed | Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. | 3.54e-08 | 8 | 167 | 4 | 25215485 | |
| Pubmed | Divergent immunoglobulin g subclass activity through selective Fc receptor binding. | 3.54e-08 | 8 | 167 | 4 | 16322460 | |
| Pubmed | Cell-derived anaphylatoxins as key mediators of antibody-dependent type II autoimmunity in mice. | 3.54e-08 | 8 | 167 | 4 | 16453025 | |
| Pubmed | C5a initiates the inflammatory cascade in immune complex peritonitis. | 3.54e-08 | 8 | 167 | 4 | 15322209 | |
| Pubmed | 3.54e-08 | 8 | 167 | 4 | 17934470 | ||
| Pubmed | 3.54e-08 | 8 | 167 | 4 | 20133862 | ||
| Pubmed | Anti-Ganglioside Antibodies Induce Nodal and Axonal Injury via Fcγ Receptor-Mediated Inflammation. | 3.54e-08 | 8 | 167 | 4 | 25926454 | |
| Pubmed | 3.54e-08 | 8 | 167 | 4 | 23610371 | ||
| Pubmed | Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines. | 3.54e-08 | 8 | 167 | 4 | 23744294 | |
| Pubmed | 3.54e-08 | 8 | 167 | 4 | 22138510 | ||
| Pubmed | 3.54e-08 | 8 | 167 | 4 | 17664287 | ||
| Pubmed | Immune complexes regulate bone metabolism through FcRγ signalling. | 3.54e-08 | 8 | 167 | 4 | 25824719 | |
| Pubmed | 6.34e-08 | 9 | 167 | 4 | 23150715 | ||
| Pubmed | A Restricted Role for FcγR in the Regulation of Adaptive Immunity. | 6.34e-08 | 9 | 167 | 4 | 29523656 | |
| Pubmed | 6.34e-08 | 9 | 167 | 4 | 27059595 | ||
| Pubmed | 1.05e-07 | 10 | 167 | 4 | 18949059 | ||
| Pubmed | 1.09e-07 | 3 | 167 | 3 | 15880819 | ||
| Pubmed | Toll-like receptor 2 ligands regulate monocyte Fcγ receptor expression and function. | 1.09e-07 | 3 | 167 | 3 | 23504312 | |
| Pubmed | 1.09e-07 | 3 | 167 | 3 | 26133275 | ||
| Pubmed | 1.09e-07 | 3 | 167 | 3 | 12427132 | ||
| Pubmed | Functional Fcgamma receptor polymorphisms are associated with human allergy. | 1.09e-07 | 3 | 167 | 3 | 24586589 | |
| Pubmed | 1.09e-07 | 3 | 167 | 3 | 12707052 | ||
| Pubmed | 1.65e-07 | 11 | 167 | 4 | 21248252 | ||
| Pubmed | 1.65e-07 | 11 | 167 | 4 | 11911824 | ||
| Pubmed | 1.65e-07 | 11 | 167 | 4 | 19795417 | ||
| Pubmed | Immunoglobulins drive terminal maturation of splenic dendritic cells. | 1.65e-07 | 11 | 167 | 4 | 23345431 | |
| Pubmed | 2.46e-07 | 12 | 167 | 4 | 31801071 | ||
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 20007534 | ||
| Pubmed | Monoallelic IRF5 deficiency in B cells prevents murine lupus. | 4.33e-07 | 4 | 167 | 3 | 34197340 | |
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 30024985 | ||
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 16452176 | ||
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 12705859 | ||
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 21169548 | ||
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 32133407 | ||
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 1379234 | ||
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 18199802 | ||
| Pubmed | 4.33e-07 | 4 | 167 | 3 | 10770797 | ||
| Pubmed | Chromosomal mapping of the high affinity Fc gamma receptor gene. | 4.94e-07 | 14 | 167 | 4 | 1347284 | |
| Pubmed | 6.72e-07 | 15 | 167 | 4 | 23345428 | ||
| Pubmed | 1.08e-06 | 5 | 167 | 3 | 17053192 | ||
| Pubmed | C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. | 1.08e-06 | 5 | 167 | 3 | 12471137 | |
| Pubmed | 1.08e-06 | 5 | 167 | 3 | 19050295 | ||
| Pubmed | 1.08e-06 | 5 | 167 | 3 | 19309690 | ||
| Pubmed | 1.08e-06 | 5 | 167 | 3 | 25345863 | ||
| Pubmed | Evidence for non-random distribution of Fcgamma receptor genotype combinations. | 1.08e-06 | 5 | 167 | 3 | 12830330 | |
| Pubmed | 1.08e-06 | 5 | 167 | 3 | 20439936 | ||
| Pubmed | Distinct regulation of murine lupus susceptibility genes by the IRF5/Blimp-1 axis. | 1.08e-06 | 5 | 167 | 3 | 22116829 | |
| Pubmed | Copy number, linkage disequilibrium and disease association in the FCGR locus. | 1.08e-06 | 5 | 167 | 3 | 20508037 | |
| Pubmed | 1.08e-06 | 5 | 167 | 3 | 16627486 | ||
| Pubmed | Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation. | DNHD1 RANBP2 POLA1 POLR2B CKAP5 WDR5 FASTKD2 CHORDC1 EPB41L3 JARID2 MRM3 MSH6 PDIA6 GUCY1B2 CSRP2 EIF2B5 PLPBP PRKCD PUM3 H2BC20P TDRD6 ALDOA | 1.44e-06 | 1425 | 167 | 22 | 30948266 |
| Pubmed | CEACAM1 induces B-cell survival and is essential for protective antiviral antibody production. | 1.49e-06 | 18 | 167 | 4 | 25692415 | |
| Pubmed | A codominant role of Fc gamma RI/III and C5aR in the reverse Arthus reaction. | 2.15e-06 | 6 | 167 | 3 | 10623857 | |
| Pubmed | 2.15e-06 | 6 | 167 | 3 | 22025304 | ||
| Pubmed | IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1. | 2.15e-06 | 6 | 167 | 3 | 22278120 | |
| Pubmed | 2.15e-06 | 6 | 167 | 3 | 16836651 | ||
| Cytoband | Xp22.1-p21.3 | 3.94e-05 | 3 | 167 | 2 | Xp22.1-p21.3 | |
| GeneFamily | LIM domain containing | 5.76e-04 | 59 | 117 | 4 | 1218 | |
| GeneFamily | WD repeat domain containing|Coronins | 8.54e-04 | 7 | 117 | 2 | 495 | |
| GeneFamily | MOB kinase activators|STRIPAK complex | 8.54e-04 | 7 | 117 | 2 | 647 | |
| GeneFamily | SUMO specific peptidases | 8.54e-04 | 7 | 117 | 2 | 984 | |
| GeneFamily | Alcohol dehydrogenases | 1.13e-03 | 8 | 117 | 2 | 397 | |
| GeneFamily | WD repeat domain containing | 1.59e-03 | 262 | 117 | 7 | 362 | |
| GeneFamily | Immunoglobulin like domain containing | 1.61e-03 | 193 | 117 | 6 | 594 | |
| GeneFamily | Tudor domain containing | 1.75e-03 | 37 | 117 | 3 | 780 | |
| GeneFamily | CD molecules|V-set domain containing|Pregnancy specific glycoproteins | 2.20e-03 | 11 | 117 | 2 | 1315 | |
| GeneFamily | Zinc fingers CXXC-type | 2.63e-03 | 12 | 117 | 2 | 136 | |
| GeneFamily | THAP domain containing | 2.63e-03 | 12 | 117 | 2 | 65 | |
| GeneFamily | PHD finger proteins|NuRD complex | 2.63e-03 | 12 | 117 | 2 | 1305 | |
| GeneFamily | Ankyrin repeat domain containing|FERM domain containing | 4.15e-03 | 50 | 117 | 3 | 1293 | |
| Coexpression | ZHANG_BREAST_CANCER_PROGENITORS_DN | 7.88e-06 | 159 | 165 | 8 | MM760 | |
| Coexpression | DESCARTES_FETAL_SPLEEN_MYELOID_CELLS | 2.10e-05 | 132 | 165 | 7 | M40289 | |
| Coexpression | MIKKELSEN_MCV6_HCP_WITH_H3K27ME3 | ADAMTS2 IRF5 TMEM215 EPB41L3 ABLIM3 CYP46A1 CORO2B SCUBE2 CHD5 KCNMA1 TDRD6 SLC7A10 | 2.31e-05 | 438 | 165 | 12 | M1954 |
| Coexpression | MIKKELSEN_MCV6_HCP_WITH_H3K27ME3 | ADAMTS2 IRF5 TMEM215 EPB41L3 ABLIM3 CYP46A1 CORO2B SCUBE2 CHD5 KCNMA1 TDRD6 SLC7A10 | 2.41e-05 | 440 | 165 | 12 | MM832 |
| ToppCell | Control|World / Disease state, Lineage and Cell class | DOCK4 RANBP2 ADAMTS2 GKN2 EPB41L3 SLC39A8 CABLES1 JARID2 KCNMA1 SLC16A10 | 2.69e-09 | 189 | 167 | 10 | fb8dddd3b901081c6bb9ed6f32dafc5cce5f30be |
| ToppCell | RA-08._Macrophage|World / Chamber and Cluster_Paper | DOCK4 EPB41L3 SLC39A8 JARID2 FCGR2A TLR2 KCNMA1 TET3 SLC16A10 | 5.09e-08 | 193 | 167 | 9 | 5fd22db1825d105709fcc0aa4955c99a117e3c82 |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_anti-infl-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | DOCK4 RANBP2 BMP2K EPB41L3 MFSD12 FCGR2C FCGR2B TLR2 SLC16A10 | 5.32e-08 | 194 | 167 | 9 | 449ce4167d64c170d914e0250f739eabedcf915d |
| ToppCell | COVID-19-kidney-Macrophages|COVID-19 / Disease (COVID-19 only), tissue and cell type | DOCK4 ADAMTS2 BMP2K EPB41L3 JARID2 FCGR2A FCGR2B TLR2 KCNMA1 | 6.07e-08 | 197 | 167 | 9 | 3912301018d0863144dcfac8d1fa8adc081748d7 |
| ToppCell | COVID-19-lung-Macrophage_LDB2hi_OSMRhi_YAP1hi|lung / Disease (COVID-19 only), tissue and cell type | BMP2K FLVCR2 EPB41L3 JARID2 FCGR2A TLR2 KCNMA1 TET3 SLC16A10 | 6.07e-08 | 197 | 167 | 9 | 3896729740d151f0eb845f1961c7b969bfbdd28d |
| ToppCell | mLN-Macrophage|mLN / Region, Cell class and subclass | DOCK4 ADAMTS2 EPB41L3 ABLIM3 FCGR1A FCGR1BP FCGR2A TLR2 KCNMA1 | 6.91e-08 | 200 | 167 | 9 | 68d709afd226241e002dae6d6820bccd1cfd87a1 |
| ToppCell | mLN-(6)_Macrophage|mLN / shred on region, Cell_type, and subtype | DOCK4 ADAMTS2 EPB41L3 ABLIM3 FCGR1A FCGR1BP FCGR2A TLR2 KCNMA1 | 6.91e-08 | 200 | 167 | 9 | 6dcba82a7d322102bae205543086e84c7655b3e0 |
| ToppCell | Control-Myeloid-Dendritic_cells|Control / group, cell type (main and fine annotations) | 4.14e-07 | 180 | 167 | 8 | 25ad95c3c30e3b82abe93bd77ba003f5c2241f7c | |
| ToppCell | 3'-Broncho-tracheal-Immune_Myeloid-Myeloid_macrophage-elicited_macrophage-Monocyte-derived_macrophage-Monocyte-derived_macrophage_L.1.2.5.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.89e-07 | 184 | 167 | 8 | d1ea2b60fb1ca1a0b809d131310c43903a9e84ce | |
| ToppCell | droplet-Lung-30m-Hematologic-myeloid-alveolar_macrophage-proliferating_alveolar_macrophage|30m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 5.09e-07 | 185 | 167 | 8 | b4af9ae4c358b48357cb135b740266e1652d886a | |
| ToppCell | NS-moderate-d_0-4-Myeloid-Non-resident_Macrophage|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 5.52e-07 | 187 | 167 | 8 | fcc32dbc9c5ae6176f154715a3e73aa32d78ad64 | |
| ToppCell | COVID-19-Heart-Macrophage|COVID-19 / Disease (COVID-19 only), tissue and cell type | 5.99e-07 | 189 | 167 | 8 | 2586f4088721c5debec86c2b211b739fd33713eb | |
| ToppCell | Children_(3_yrs)-Immune-interstitial_macrophage_(C1Q_positive)|Children_(3_yrs) / Lineage, Cell type, age group and donor | 6.23e-07 | 190 | 167 | 8 | f573fef3762a30c38cf8fa7f45df0ffbb49dc873 | |
| ToppCell | Children_(3_yrs)-Immune-interstitial_macrophage_(C1Q_positive)-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 6.23e-07 | 190 | 167 | 8 | 2d54fca50593fbd11fe13fc2bfaf937a05db776d | |
| ToppCell | Control-Myeloid-Macrophage|World / Disease state, Lineage and Cell class | 7.29e-07 | 194 | 167 | 8 | c35bf04d5e7450cb6679a036fcabb1b28f409f29 | |
| ToppCell | COPD-Myeloid-Macrophage|World / Disease state, Lineage and Cell class | 7.29e-07 | 194 | 167 | 8 | 7d682408e9a6239a4e47befc9376e760cc3d133a | |
| ToppCell | RA-08._Macrophage|RA / Chamber and Cluster_Paper | 7.29e-07 | 194 | 167 | 8 | ac26e5c71d5069622de72fa25a9c920887ac2c19 | |
| ToppCell | COVID-19-lung-Macrophage_CD163hi_MERTKhi|lung / Disease (COVID-19 only), tissue and cell type | 7.58e-07 | 195 | 167 | 8 | 148fff8c3c9ba45ec36e98dff1be57e3f8294506 | |
| ToppCell | COVID-19-lung-Macrophage_CD163hi_MERTKhi|COVID-19 / Disease (COVID-19 only), tissue and cell type | 7.88e-07 | 196 | 167 | 8 | 7026c1fc33425e5476063d17c79e4b79356a9e01 | |
| ToppCell | COVID-19-Myeloid-MoAM1,_IL1R2|COVID-19 / Condition, Lineage and Cell class | 8.18e-07 | 197 | 167 | 8 | 4a9c61b37c938bb26929593007d713382ae1eb79 | |
| ToppCell | nucseq-Immune-Immune_Myeloid-IM|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 8.18e-07 | 197 | 167 | 8 | 6f41c8f815851968849428ec92c16745bd01a3fb | |
| ToppCell | nucseq-Immune-Immune_Myeloid-IM-IM|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 8.18e-07 | 197 | 167 | 8 | 304044ace926943b8eb588f686ecbe5d1689a809 | |
| ToppCell | COVID-19-Myeloid|COVID-19 / group, cell type (main and fine annotations) | 8.50e-07 | 198 | 167 | 8 | 33f0a919188a67d2a876b52c61a1cec2c9747969 | |
| ToppCell | VE-mono1-|VE / Condition, Cell_class and T cell subcluster | 8.50e-07 | 198 | 167 | 8 | 2959d6e4992c36040ec9637f5a2daed02b35cf30 | |
| ToppCell | VE-mono1|VE / Condition, Cell_class and T cell subcluster | 8.50e-07 | 198 | 167 | 8 | c742871b8ec4720b1848991551c7c1f4000ebd85 | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Myeloid-TAM-BDM|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 8.83e-07 | 199 | 167 | 8 | 0d447ca1a77120aac068857ff0ddc2ed6942ed3e | |
| ToppCell | COPD-Myeloid-Macrophage|COPD / Disease state, Lineage and Cell class | 8.83e-07 | 199 | 167 | 8 | 4b9c53fb4f44190d2f6ad4d52b13be01ebe4955e | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_no-steroids-Myeloid-Macrophage-macrophage,_alveolar-Macro_c2-CCL3L1|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 8.83e-07 | 199 | 167 | 8 | d3f77acb36ac7c56a47ca98b695f46ae5b9ecd12 | |
| ToppCell | IPF-Myeloid-Macrophage|Myeloid / Disease state, Lineage and Cell class | 8.83e-07 | 199 | 167 | 8 | 3c2b362d5e824e1a04830e70352f8818de984174 | |
| ToppCell | Tracheal-10x5prime-Immune_Myeloid-Macrophage_other-Macro_AW_CX3CR1|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 9.17e-07 | 200 | 167 | 8 | 27f498bcd706d0751091662996795b5270e46f14 | |
| ToppCell | (61)_LYVE1_Macrophage|World / shred on Cell_type and subtype | 1.14e-06 | 206 | 167 | 8 | 711e961a9a03bfd2f0958bd14f25f7f207a2f2b5 | |
| ToppCell | facs-Lung-nan-3m-Myeloid-Intermediate_Monocyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.09e-06 | 156 | 167 | 7 | 3f0b9e35d4da85c90759b930052e5b9c3cde9b15 | |
| ToppCell | facs-Lung-nan-3m-Myeloid-intermediate_monocyte|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.09e-06 | 156 | 167 | 7 | 69e6e8810d1738a66c9821910f41498931cf30cc | |
| ToppCell | TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Mucinous_Colon_Adenocarcinoma|TCGA-Colorectal / Sample_Type by Project: Shred V9 | 2.92e-06 | 164 | 167 | 7 | 3c15e9b8403b03d67f6ecd7861dc19f1261e3244 | |
| ToppCell | mild-Myeloid-CD14_Monocytes_3|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 3.04e-06 | 165 | 167 | 7 | a6547bb2c9c40b4878325da19b9def0ef644fa25 | |
| ToppCell | PND01-Immune-Immune_Myeloid-Monocytic-Macrophage-iMON|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.70e-06 | 170 | 167 | 7 | a6f2a792980e6a1025b8f1b0eda442a555938488 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Immune-Myeloid|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 6.01e-06 | 183 | 167 | 7 | a97f052950429245c3231464271e1ba539863bba | |
| ToppCell | 10x_3'_v3-tissue-resident_(10x_3'_v3)-myeloid-myeloid_dendritic-CD1c-positive_myeloid_dendritic_cell|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 6.68e-06 | 186 | 167 | 7 | 0dce13e15c3bf32610bf2dad31253b52a39cff87 | |
| ToppCell | Fetal_29-31_weeks-Immune-interstitial_macrophage_(C1Q_positive)-D088|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 7.17e-06 | 188 | 167 | 7 | 3be2d50148daa4eddddc2c7f269f45c97f7e4931 | |
| ToppCell | Smart-seq2-lymph_node_(Smart-seq2)-myeloid|lymph_node_(Smart-seq2) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 7.42e-06 | 189 | 167 | 7 | 2aebea7a6c2f83112d7c504b742f2c04b92e459a | |
| ToppCell | Control-Myeloid-Transitioning_MDM|Control / group, cell type (main and fine annotations) | 7.68e-06 | 190 | 167 | 7 | d6fd8c23cde4a10cc1517b6899a5a855fdfff2e2 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_aging_sig-E|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 7.68e-06 | 190 | 167 | 7 | 0a944da2aaaef9289b2a4ffe360b0338724fd59b | |
| ToppCell | MatrixFB-Fibroblast-D_(Pericyte)|MatrixFB / shred on cell class and cell subclass (v4) | 8.22e-06 | 192 | 167 | 7 | 630444302511f511ec6976bc045a3b4b9d8d4547 | |
| ToppCell | COVID-19-Myeloid-MoAM1,_IL1R2|Myeloid / Condition, Lineage and Cell class | 8.22e-06 | 192 | 167 | 7 | be9d5685fa03563322f147a4b38ed31e4da59487 | |
| ToppCell | E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC-VSMC_mature|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 8.50e-06 | 193 | 167 | 7 | 323d1f3f4fbeb93ba857fc135d8aa0b897f98ac5 | |
| ToppCell | PND03-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 8.50e-06 | 193 | 167 | 7 | 800b0f5705fefcd3608e37801afae8a94474723e | |
| ToppCell | renal_papilla_nuclei-Adult_normal_reference-Immune-Myeloid-Macrophage_Dendritic-M2_Macrophage|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 8.50e-06 | 193 | 167 | 7 | 374d0526a071e973c3f43b4564f78f6933bb67ed | |
| ToppCell | Control-Myeloid-Macrophage|Myeloid / Disease state, Lineage and Cell class | 8.50e-06 | 193 | 167 | 7 | 2a6d531abd34df20941cf3dac4fdfb1621a1bde6 | |
| ToppCell | COVID-19-Heart-Macrophage|Heart / Disease (COVID-19 only), tissue and cell type | 8.80e-06 | 194 | 167 | 7 | f09675cd472200363c458952f00d2e41990800ee | |
| ToppCell | LA-08._Macrophage|World / Chamber and Cluster_Paper | 8.80e-06 | 194 | 167 | 7 | c1805572bcc11b1cd29083329d7b5911489fb758 | |
| ToppCell | COVID-19-Myeloid-Monocyte-derived_macrophages|COVID-19 / group, cell type (main and fine annotations) | 9.09e-06 | 195 | 167 | 7 | c172c5599379c29123340621a36bfb1fc90c2115 | |
| ToppCell | LA-08._Macrophage|LA / Chamber and Cluster_Paper | 9.09e-06 | 195 | 167 | 7 | 5e1d5bdb8874091f5a2b1d0a8cc9008165718a97 | |
| ToppCell | 10x_3'_v3-bone_marrow_(10x_3'_v3)-myeloid-myeloid_macrophage|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 9.09e-06 | 195 | 167 | 7 | 4e9513a7ea69fa9fc8e9ff2da8ef3f44e8fdc70d | |
| ToppCell | 10x_3'_v3-bone_marrow_(10x_3'_v3)-myeloid-myeloid_macrophage-macrophage|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 9.09e-06 | 195 | 167 | 7 | a25a342380e258b784227f7298f609ccaa1f9ce7 | |
| ToppCell | COVID-19-Myeloid-Transitioning_MDM|COVID-19 / group, cell type (main and fine annotations) | 9.40e-06 | 196 | 167 | 7 | 4929cfed1f150c1fde4d79cb49895c2ea467a18f | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_hypoxia|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 9.40e-06 | 196 | 167 | 7 | a44a648bf209ce037bfc7b3adfcb220aab60728c | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-TAM-MG-TAM-MG_aging_sig-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 9.40e-06 | 196 | 167 | 7 | e54c08f88779f9fd453a4f5b85aed1f460d8a1e1 | |
| ToppCell | COVID-19_Mild-Classical_Monocyte-cMono_3|Classical_Monocyte / Disease condition and Cell class | 9.40e-06 | 196 | 167 | 7 | 15397ec27167bb2fb6fec120b68bf38fc71b2670 | |
| ToppCell | (6)_Macrophage|World / shred on Cell_type and subtype | 9.72e-06 | 197 | 167 | 7 | 010b275d4da4a896175ad7fbaa96d1dc11a0b744 | |
| ToppCell | Parenchymal-10x3prime_v2-Immune_Myeloid-Macrophage_other-Macro_CHIT1|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 1.00e-05 | 198 | 167 | 7 | 243109377d62d20c69e9d1fedc252156e90cda1e | |
| ToppCell | Bronchial-NucSeq-Immune_Myeloid-Macrophage_other-Macrophage_intravascular|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.00e-05 | 198 | 167 | 7 | c7dbf24caae5c4ef285845d13055de9e07281bb3 | |
| ToppCell | Caecum-(6)_Macrophage-(61)_LYVE1_Macrophage|Caecum / shred on region, Cell_type, and subtype | 1.00e-05 | 198 | 167 | 7 | e684c3934c163aef4d284b69435832d2c9614f2a | |
| ToppCell | COVID-19-kidney-Macrophages|kidney / Disease (COVID-19 only), tissue and cell type | 1.00e-05 | 198 | 167 | 7 | 161324541fe5da5cbb58142ea94fefd39b7dfb04 | |
| ToppCell | Caecum-Macrophage-LYVE1_Macrophage|Caecum / Region, Cell class and subclass | 1.00e-05 | 198 | 167 | 7 | a92c0cacb775aca6bbb302bd9e22c081a112a44d | |
| ToppCell | NS-moderate-d_0-4-Myeloid|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.00e-05 | 198 | 167 | 7 | 1791f1b1195ac1735ca2c1e6adf04a7f39d63ac1 | |
| ToppCell | Tracheal-NucSeq-Immune_Myeloid-Monocytic-Monocyte_CD16|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.00e-05 | 198 | 167 | 7 | 0b928a829844f49f4d47e88908af192cb919011f | |
| ToppCell | distal-2-Hematologic-Interstitial_Macrophage|2 / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.04e-05 | 199 | 167 | 7 | d4caf296b6ce22a10b78d0efd4e018d867ccb78a | |
| ToppCell | COPD-Myeloid-Macrophage|Myeloid / Disease state, Lineage and Cell class | 1.04e-05 | 199 | 167 | 7 | 1cf1b2d6debf9e3389f1829dcaa2857e9533a080 | |
| ToppCell | mLN-(4)_Monocyte|mLN / shred on region, Cell_type, and subtype | 1.04e-05 | 199 | 167 | 7 | 6795ff31f92580195c9db776951f99d647484d24 | |
| ToppCell | 10x5'v1-week_17-19-Myeloid_macrophage-stroma-stromal_macrophage|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 1.04e-05 | 199 | 167 | 7 | 2649afa3ccda78e9d1df26127b66cbfa0c6cd01d | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Macrophage|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.04e-05 | 199 | 167 | 7 | c4fc638a8dad3a9b77634e8912a9326c8a2f11f5 | |
| ToppCell | cellseq2-Immune-Immune_Myeloid-IM-IM|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.04e-05 | 199 | 167 | 7 | 372fb9eb90022dc4ac770a75b4e207c33d1d0c43 | |
| ToppCell | mLN-Monocyte-Monocyte|mLN / Region, Cell class and subclass | 1.04e-05 | 199 | 167 | 7 | dcee372774c169a3048bdaed3734b3215bf8ffad | |
| ToppCell | Parenchymal-NucSeq-Immune_Myeloid-Macrophage_other-Macro_interstitial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.04e-05 | 199 | 167 | 7 | 841338719d042247966867ac608146395eb8c4d9 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_anti-infl-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.04e-05 | 199 | 167 | 7 | 667b8b47a5b388506e3177b46747267fad8024f6 | |
| ToppCell | mLN-(4)_Monocyte-(40)_Monocyte|mLN / shred on region, Cell_type, and subtype | 1.04e-05 | 199 | 167 | 7 | bcbb1eee8d79bf670dbe113094c3a292b135ce2f | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_anti-infl-Z|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.04e-05 | 199 | 167 | 7 | 45e2f44a0ed39cb9ba061a03874c1fe746856c2d | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Myeloid-TAM-BDM-TAM-BDM_anti-infl|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 1.04e-05 | 199 | 167 | 7 | de9c1c801eb34faf01760df07d5ff6bbd561e152 | |
| ToppCell | mLN-Monocyte|mLN / Region, Cell class and subclass | 1.04e-05 | 199 | 167 | 7 | 241f790cd5d8a9b2451333deecc826a673bae70a | |
| ToppCell | VE-granulo2|VE / Condition, Cell_class and T cell subcluster | 1.04e-05 | 199 | 167 | 7 | 05b47fdc01eccee0eaf4c781eeff93c47fe0533e | |
| ToppCell | cellseq2-Immune-Immune_Myeloid-IM|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.04e-05 | 199 | 167 | 7 | dd3bf59cdc18091889cbf6c43f37100ba537843d | |
| ToppCell | cellseq2-Immune-Immune_Myeloid|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.04e-05 | 199 | 167 | 7 | 6c3c9eceea20121ae17ae2462134aa0437f591b3 | |
| ToppCell | VE-granulo2-|VE / Condition, Cell_class and T cell subcluster | 1.04e-05 | 199 | 167 | 7 | 455e92047201ddd0c29a437a838e5fa135de7995 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Macrophage-macrophage,_alveolar|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.04e-05 | 199 | 167 | 7 | 697a9a58c0cdb77222700d029873355d37f6ab28 | |
| ToppCell | Parenchymal-NucSeq-Immune_Myeloid-Macrophage_other-Macrophage_intravascular|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.07e-05 | 200 | 167 | 7 | 179afc4bee7a2fd85a3b5dadf32544a63807c164 | |
| ToppCell | Transverse-(6)_Macrophage|Transverse / shred on region, Cell_type, and subtype | 1.07e-05 | 200 | 167 | 7 | b28350de555fa756d2631f004f71d5ac69b1affe | |
| ToppCell | Transverse-Monocyte|Transverse / Region, Cell class and subclass | 1.07e-05 | 200 | 167 | 7 | d70aeb57b98496474b97906505576640fdbdf34c | |
| ToppCell | Parenchymal-10x3prime_v2-Immune_Myeloid-Macrophage_other-Macrophage_intravascular|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 1.07e-05 | 200 | 167 | 7 | 4b4df0fe47498310d94448b8a289e58e4f5b5aa8 | |
| ToppCell | Sigmoid-Macrophage|Sigmoid / Region, Cell class and subclass | 1.07e-05 | 200 | 167 | 7 | b07ac0ff3b8530e99094678fed80f35949cafac8 | |
| ToppCell | Caecum-(6)_Macrophage|Caecum / shred on region, Cell_type, and subtype | 1.07e-05 | 200 | 167 | 7 | 2ce3930645c3daf6be578f7881e57a58df61e75c | |
| ToppCell | mild-CD163+_Monocytes_(Sample_ID1_d7)|World / Cohort 1 (10x PBMC) with disease condition, cell group and cell class | 1.07e-05 | 200 | 167 | 7 | 82126e25bfd8fba78dc1348fa5ad6a576289a139 | |
| ToppCell | Sigmoid-(6)_Macrophage|Sigmoid / shred on region, Cell_type, and subtype | 1.07e-05 | 200 | 167 | 7 | 9e10cca4429de2c4c8c3c6cf2c9e28637a095be9 | |
| ToppCell | Transverse-(4)_Monocyte|Transverse / shred on region, Cell_type, and subtype | 1.07e-05 | 200 | 167 | 7 | 85714e8da539366b5bce071dfea8f8055de527bc | |
| ToppCell | Transverse-Monocyte-Monocyte|Transverse / Region, Cell class and subclass | 1.07e-05 | 200 | 167 | 7 | 96ecfab57e998134e164b4a62881ef6f2612bd8d | |
| ToppCell | Parenchymal-10x5prime-Immune_Myeloid-Macrophage_other|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.07e-05 | 200 | 167 | 7 | eac46978e2b3d38cf42b44f7b0350d0489d036b3 | |
| ToppCell | Parenchymal-10x3prime_v2-Immune_Myeloid-Macrophage_other|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 1.07e-05 | 200 | 167 | 7 | 1a080564de59abd59d3208a73441b6346e1c7cd8 | |
| ToppCell | Sigmoid-Macrophage-Macrophage|Sigmoid / Region, Cell class and subclass | 1.07e-05 | 200 | 167 | 7 | 9ee3a799de7bade1bfe94b6827461633f02bc1dc | |
| ToppCell | mLN-(6)_Macrophage-(61)_LYVE1_Macrophage|mLN / shred on region, Cell_type, and subtype | 1.07e-05 | 200 | 167 | 7 | a20f5ec61d492d8a2adf695ec304b5d57296aa8f | |
| ToppCell | mLN-Macrophage-LYVE1_Macrophage|mLN / Region, Cell class and subclass | 1.07e-05 | 200 | 167 | 7 | 89cf739a3c2f5d30e547404f2f2ec6500cd1d65d | |
| ToppCell | Transverse-Macrophage|Transverse / Region, Cell class and subclass | 1.07e-05 | 200 | 167 | 7 | 1920605e5811938814d02b971069a4506868db5f | |
| Drug | TAN-1030A | 3.94e-08 | 6 | 165 | 4 | CID009576886 | |
| Drug | AC1MHTIN | 9.15e-08 | 7 | 165 | 4 | CID003011133 | |
| Drug | TAN-999 | 9.15e-08 | 7 | 165 | 4 | CID000130283 | |
| Drug | Intravenous Immunoglobulin | 1.82e-07 | 8 | 165 | 4 | DB00028 | |
| Drug | Palivizumab | 5.40e-07 | 10 | 165 | 4 | DB00110 | |
| Drug | Bevacizumab | 8.44e-07 | 11 | 165 | 4 | DB00112 | |
| Drug | Tositumomab | 8.44e-07 | 11 | 165 | 4 | DB00081 | |
| Drug | Alemtuzumab | 8.44e-07 | 11 | 165 | 4 | DB00087 | |
| Drug | Efalizumab | 8.44e-07 | 11 | 165 | 4 | DB00095 | |
| Drug | Alefacept | 8.44e-07 | 11 | 165 | 4 | DB00092 | |
| Drug | Daclizumab | 1.26e-06 | 12 | 165 | 4 | DB00111 | |
| Drug | Natalizumab | 1.26e-06 | 12 | 165 | 4 | DB00108 | |
| Drug | Rituximab | 1.26e-06 | 12 | 165 | 4 | DB00073 | |
| Drug | Ibritumomab | 1.26e-06 | 12 | 165 | 4 | DB00078 | |
| Drug | Adalimumab | 1.26e-06 | 12 | 165 | 4 | DB00051 | |
| Drug | Gemtuzumab ozogamicin | 1.26e-06 | 12 | 165 | 4 | DB00056 | |
| Drug | Cetuximab | 1.26e-06 | 12 | 165 | 4 | DB00002 | |
| Drug | Trastuzumab | 1.81e-06 | 13 | 165 | 4 | DB00072 | |
| Drug | Basiliximab | 1.81e-06 | 13 | 165 | 4 | DB00074 | |
| Drug | Abciximab | 2.52e-06 | 14 | 165 | 4 | DB00054 | |
| Drug | Etanercept | 2.52e-06 | 14 | 165 | 4 | DB00005 | |
| Drug | Muromonab | 3.41e-06 | 15 | 165 | 4 | DB00075 | |
| Drug | MDL 20,610 | 3.70e-06 | 5 | 165 | 3 | CID000128209 | |
| Drug | R13-1 | 9.47e-06 | 19 | 165 | 4 | CID000009666 | |
| Drug | AC1NS1CY | 1.01e-05 | 40 | 165 | 5 | CID005326941 | |
| Drug | superoxide | HECW1 TYK2 BLM FCGR2C CORO2B DHDH FCGR1A FCGR2A FCGR2B KAT8 PRKCD UQCRFS1 UROD EIF2AK3 | 1.42e-05 | 490 | 165 | 14 | CID000520535 |
| Drug | Loestrin | 1.45e-05 | 21 | 165 | 4 | CID000062925 | |
| Drug | AC1Q5JRE | 1.76e-05 | 22 | 165 | 4 | CID000188349 | |
| Drug | AC1NSK5W | 3.04e-05 | 9 | 165 | 3 | CID005311182 | |
| Drug | Denny-Jaffe reagent | 4.32e-05 | 10 | 165 | 3 | CID003035979 | |
| Drug | sodiosodium | 4.47e-05 | 54 | 165 | 5 | CID000141233 | |
| Drug | 17-AAG; Up 200; 1uM; PC3; HT_HG-U133A | 6.82e-05 | 187 | 165 | 8 | 1218_UP | |
| Drug | NA-1 | 8.72e-05 | 62 | 165 | 5 | CID000446091 | |
| Drug | DAPH; Up 200; 10uM; PC3; HG-U133A | 1.05e-04 | 199 | 165 | 8 | 578_UP | |
| Disease | inflammatory bowel disease (implicated_via_orthology) | 9.17e-06 | 25 | 158 | 4 | DOID:0050589 (implicated_via_orthology) | |
| Disease | malaria (implicated_via_orthology) | 1.24e-05 | 9 | 158 | 3 | DOID:12365 (implicated_via_orthology) | |
| Disease | Systemic lupus erythematosus | 2.41e-05 | 11 | 158 | 3 | cv:C0024141 | |
| Disease | secretory phospholipase A2 receptor measurement | 8.52e-05 | 3 | 158 | 2 | EFO_0802043 | |
| Disease | low affinity immunoglobulin gamma Fc region receptor II-a measurement | 9.69e-05 | 17 | 158 | 3 | EFO_0021969 | |
| Disease | Colorectal Carcinoma | PCSK2 ADAM19 ABCA13 LAMA1 GPR87 MFN1 CABLES1 MSH6 CORO2B CHD5 TLR2 CPO ANAPC4 | 1.10e-04 | 702 | 158 | 13 | C0009402 |
| Disease | Malaria | 1.61e-04 | 20 | 158 | 3 | C0024530 | |
| Disease | rheumatoid arthritis | CXCL13 IRF5 TYK2 CUL5 APOM GUCY1B2 FCGR2A FCGR2B TET3 ANAPC4 | 2.05e-04 | 462 | 158 | 10 | EFO_0000685 |
| Disease | alcohol dependence measurement | 2.18e-04 | 55 | 158 | 4 | EFO_0007835 | |
| Disease | C-X-C motif chemokine 10 measurement | 3.08e-04 | 109 | 158 | 5 | EFO_0008056 | |
| Disease | low affinity immunoglobulin gamma Fc region receptor II-b measurement | 3.18e-04 | 25 | 158 | 3 | EFO_0021970 | |
| Disease | SYSTEMIC LUPUS ERYTHEMATOSUS | 4.21e-04 | 6 | 158 | 2 | 152700 | |
| Disease | low affinity immunoglobulin gamma Fc region receptor II-a/b measurement | 5.88e-04 | 7 | 158 | 2 | EFO_0008211 | |
| Disease | lymphoid leukemia (is_implicated_in) | 5.88e-04 | 7 | 158 | 2 | DOID:1037 (is_implicated_in) | |
| Disease | Uterine leiomyoma, breast carcinoma | 6.67e-04 | 32 | 158 | 3 | EFO_0000305, HP_0000131 | |
| Disease | QT interval, response to tricyclic antidepressant | 7.81e-04 | 8 | 158 | 2 | EFO_0004682, EFO_0007916 | |
| Disease | anti-centromere-antibody-positive systemic scleroderma | 1.00e-03 | 9 | 158 | 2 | EFO_0008536 | |
| Disease | plexin-B2 measurement | 1.00e-03 | 9 | 158 | 2 | EFO_0021867 | |
| Disease | Autism Spectrum Disorders | 1.14e-03 | 85 | 158 | 4 | C1510586 | |
| Disease | forced expiratory volume | ADAM19 BMP2K CKAP5 ABLIM3 CABLES1 SCUBE2 TULP4 CPO PARL KCNMA1 EIF2AK3 ANAPC4 | 1.16e-03 | 789 | 158 | 12 | EFO_0004314 |
| Disease | aspartate aminotransferase measurement | PDE3A DNAJC13 HECTD4 DVL2 MFSD12 SLC39A8 ADH4 FCGR2C FCGR2A FCGR2B PUM3 LTBR LY75 | 1.20e-03 | 904 | 158 | 13 | EFO_0004736 |
| Disease | visceral adipose tissue measurement, body mass index | 1.25e-03 | 87 | 158 | 4 | EFO_0004340, EFO_0004765 | |
| Disease | diffuse scleroderma (is_implicated_in) | 1.52e-03 | 11 | 158 | 2 | DOID:1580 (is_implicated_in) | |
| Disease | Macrocephaly | 1.52e-03 | 11 | 158 | 2 | C0221355 | |
| Disease | factor VIII deficiency (is_implicated_in) | 1.52e-03 | 11 | 158 | 2 | DOID:12134 (is_implicated_in) | |
| Disease | Ashkenazi Jewish disorders | 1.52e-03 | 11 | 158 | 2 | cv:CN118946 | |
| Disease | systemic lupus erythematosus (implicated_via_orthology) | 1.59e-03 | 43 | 158 | 3 | DOID:9074 (implicated_via_orthology) | |
| Disease | uric acid measurement | DNAJC13 HECTD4 EPB41L3 MFSD12 SLC39A8 CD200R1 CEMIP SLC10A2 ANAPC4 SLC16A10 | 1.72e-03 | 610 | 158 | 10 | EFO_0004761 |
| Disease | Intestinal Neoplasms | 1.82e-03 | 12 | 158 | 2 | C0021841 | |
| Disease | Intestinal Cancer | 1.82e-03 | 12 | 158 | 2 | C0346627 | |
| Disease | Thrombus | 1.93e-03 | 46 | 158 | 3 | C0087086 | |
| Disease | Primary biliary cirrhosis | 2.06e-03 | 47 | 158 | 3 | C0008312 | |
| Disease | autoimmune thrombocytopenic purpura (is_marker_for) | 2.14e-03 | 13 | 158 | 2 | DOID:8924 (is_marker_for) | |
| Disease | Thrombosis | 2.32e-03 | 49 | 158 | 3 | C0040053 | |
| Disease | eosinophil percentage of leukocytes | ADAM19 NAGK IRF5 SLC39A8 CD200R1 CABLES1 LTBR ALDOA MUC2 TET3 SLC7A10 | 2.35e-03 | 746 | 158 | 11 | EFO_0007991 |
| Disease | lung adenocarcinoma | 2.51e-03 | 174 | 158 | 5 | EFO_0000571 | |
| Disease | red blood cell density measurement | BMP2K SMG5 SLC39A8 CD200R1 FCGR2C C6orf118 SPPL2A PHF20L1 FCGR2B LY75 SLC7A10 SLC16A10 | 2.86e-03 | 880 | 158 | 12 | EFO_0007978 |
| Disease | autoimmune thrombocytopenic purpura (is_implicated_in) | 2.86e-03 | 15 | 158 | 2 | DOID:8924 (is_implicated_in) | |
| Disease | Malaria, susceptibility to | 3.25e-03 | 16 | 158 | 2 | cv:C1970028 | |
| Disease | – | 3.25e-03 | 16 | 158 | 2 | 611162 | |
| Disease | phosphatidylcholine 38:6 measurement | 3.25e-03 | 16 | 158 | 2 | EFO_0010388 | |
| Disease | factor XI measurement, fibrinogen measurement, tissue plasminogen activator measurement, factor VII measurement | 3.39e-03 | 56 | 158 | 3 | EFO_0004619, EFO_0004623, EFO_0004694, EFO_0004791 | |
| Disease | Glycogen storage disease | 3.68e-03 | 17 | 158 | 2 | cv:C0017919 | |
| Disease | perinatal necrotizing enterocolitis (biomarker_via_orthology) | 3.68e-03 | 17 | 158 | 2 | DOID:8677 (biomarker_via_orthology) | |
| Disease | Libman-Sacks Disease | 3.75e-03 | 58 | 158 | 3 | C0242380 | |
| Disease | fibrinogen measurement, factor VII measurement | 3.75e-03 | 58 | 158 | 3 | EFO_0004619, EFO_0004623 | |
| Disease | chronic obstructive pulmonary disease | ADAM19 CDC20B ABLIM3 AFAP1 SPPL2A DTWD1 SCUBE2 TLE1 LTBR PDZD2 | 4.07e-03 | 688 | 158 | 10 | EFO_0000341 |
| Disease | schizophrenia, inflammatory bowel disease | 4.12e-03 | 18 | 158 | 2 | EFO_0003767, MONDO_0005090 | |
| Disease | systemic lupus erythematosus (is_implicated_in) | 4.52e-03 | 62 | 158 | 3 | DOID:9074 (is_implicated_in) | |
| Disease | limited scleroderma | 4.59e-03 | 19 | 158 | 2 | EFO_1001017 | |
| Disease | rheumatoid arthritis, ACPA-positive rheumatoid arthritis, rheumatoid factor seropositivity measurement | 4.73e-03 | 63 | 158 | 3 | EFO_0000685, EFO_0007791, EFO_0009459 | |
| Disease | Sarcomatoid Renal Cell Carcinoma | 5.05e-03 | 128 | 158 | 4 | C1266043 | |
| Disease | Chromophobe Renal Cell Carcinoma | 5.05e-03 | 128 | 158 | 4 | C1266042 | |
| Disease | Collecting Duct Carcinoma of the Kidney | 5.05e-03 | 128 | 158 | 4 | C1266044 | |
| Disease | Papillary Renal Cell Carcinoma | 5.05e-03 | 128 | 158 | 4 | C1306837 | |
| Disease | Renal Cell Carcinoma | 5.05e-03 | 128 | 158 | 4 | C0007134 | |
| Disease | unipolar depression, bipolar disorder, schizophrenia | 5.08e-03 | 20 | 158 | 2 | EFO_0003761, MONDO_0004985, MONDO_0005090 | |
| Disease | Astigmatism | 5.19e-03 | 129 | 158 | 4 | HP_0000483 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| KCVLAGVKPSLGIWT | 606 | Q9BXT4 | |
| DEVARLWGIRKCKPH | 76 | A0A1W2PQ73 | |
| VWHPICKQAARAEKK | 256 | O94929 | |
| KDGLCVPRKWIYHLT | 91 | O95445 | |
| KEVTCLAWRPDGKLL | 66 | Q9UJX5 | |
| CLWDDKGPAKIHQAL | 51 | Q93034 | |
| TCPPLKGKVQRILHW | 461 | Q8TDI0 | |
| CTPIASAWLLKDGKV | 336 | Q9NZJ5 | |
| GVFWRSKPKCVHRLT | 466 | Q9NS82 | |
| KAAIAWEAGKPLCIE | 11 | P08319 | |
| QVIRCKAAILWKPGA | 6 | P28332 | |
| WTELPEQKPRAKHSC | 936 | Q9H013 | |
| SPCRGHVLRKAKEWE | 711 | Q8N556 | |
| AKWRCVLKIGEHTPS | 146 | P04075 | |
| LRCHSWKDKPLVKVT | 141 | P12318 | |
| RCHSWKDKPLVKVTF | 151 | P31994 | |
| LPGDKRTKHICVYWE | 131 | Q86SQ3 | |
| KHDEWLSCAPKTRPQ | 56 | O94983 | |
| HVPKRWGCLADLFKV | 4991 | Q86UQ4 | |
| ATGNVIWKHSCGKPL | 926 | Q4L235 | |
| WKSHPIAGILEVRGC | 651 | Q96M86 | |
| KPITTKADIWALGCL | 241 | Q9NSY1 | |
| NPKKIIWMDCGIHAR | 96 | Q8IVL8 | |
| EKISDLWKAHPGKIC | 341 | Q8WUJ3 | |
| KLGIWFCLTLKALPH | 226 | Q96KC8 | |
| RVTSLGKDWHRPCLK | 16 | P50238 | |
| VHKPGPIVLTVAKCW | 341 | O14641 | |
| FKGHCIWLTPDILKR | 546 | O95450 | |
| KIGLPILCVGSVWKS | 261 | Q9UJ70 | |
| VTPKKEGHWDCSICL | 1411 | P49792 | |
| GKHQWDLDTCKGLLP | 71 | Q7Z6M1 | |
| DSIWKCLKFLGSRHP | 501 | Q96HW7 | |
| CLWHGTPKDRKVIVK | 371 | Q15397 | |
| DLKAGCLVRVFWPKA | 151 | Q8IWA4 | |
| EKWGKITALPRAHTC | 1526 | Q9P2P5 | |
| GLDWTVAPKKARECV | 281 | P06132 | |
| EGEPLALRCHAWKDK | 116 | Q92637 | |
| KLHTSTCWLQEVPGK | 76 | Q2VYF4 | |
| HWCAPKEIEKVILTR | 816 | Q12791 | |
| GKKVAERSCASPLWH | 346 | Q6ZNB6 | |
| LKRVHPDTGIWCKAM | 46 | Q6DN03 | |
| LKRVHPDTGIWCKAM | 46 | Q6DRA6 | |
| KGVQCQRWSAETPHK | 371 | Q2TV78 | |
| LWKLHNGDLCSPKRS | 1231 | Q9ULD2 | |
| LPRVSGTHIKLWKLC | 646 | Q9NXD2 | |
| HCGSLLWGLVKQGLK | 246 | Q05655 | |
| KWGKITSLPRAHTCF | 1561 | Q76N89 | |
| ITVDSVCLKWAPPKH | 436 | Q9H7Z6 | |
| EIVELAKGACPWKEH | 261 | Q9HB07 | |
| QIKEHLLKSKWCRPT | 101 | Q13144 | |
| RCHSWKDKPLVKVTF | 151 | P31995 | |
| IKLLTVIKWHGPKCN | 531 | Q9NZN1 | |
| HWCSLLKKTETPFGR | 586 | Q02817 | |
| RKTHQGPVLDVGCIW | 106 | O15018 | |
| INGPAKCKELHLQWT | 951 | Q14432 | |
| GVAPWKLKIFHCQVT | 76 | O14626 | |
| VHAARGKWGIKANCP | 1111 | Q7LBC6 | |
| GNCVLLDPKGTWKHE | 1486 | O60449 | |
| LDPKGTWKHEKCNSV | 1491 | O60449 | |
| VCKAVAGKPAAHISW | 166 | Q8TD46 | |
| HWADGTNIKKPIKCS | 96 | Q7L9L4 | |
| VNGEKKLFCIPWRHA | 36 | Q13568 | |
| VLGTGWPKDLVKCIS | 706 | Q9Y4D8 | |
| HTPFGKRLLKQWLCA | 766 | P52701 | |
| CVIGILLHNAWKGKP | 56 | Q8TDV0 | |
| EKIAIWLKDCRTPLG | 76 | P28290 | |
| RGNGCPRKEIIVWKK | 56 | O43927 | |
| INVCKAPHWSKIGRL | 651 | P09884 | |
| DCSKLKSPLGVKWHT | 191 | Q9BY21 | |
| KIDRATCPQHLKWKD | 401 | P32942 | |
| TCPQHLKWKDKTRHV | 406 | P32942 | |
| YCPLKEWVAGKVHLI | 576 | A2A2Y4 | |
| PVDQKCEHKLWKARL | 11 | Q14008 | |
| DWFLLGSPIEKLCKH | 131 | Q86XP6 | |
| KRPELGVTLTKLHCW | 76 | P46976 | |
| PKKVAFDCLEWIRKH | 871 | P54132 | |
| PKVCGHQGNVLDIKW | 81 | Q9UQ03 | |
| DLLKWRTHPDKITGC | 586 | Q8N1I0 | |
| KIIGAGKPWHKNCFR | 131 | Q16527 | |
| QWPCGKHKRVLIFPS | 466 | Q8TDN4 | |
| LPCFWKKDEVGGRVL | 46 | Q9Y6A2 | |
| LDNICHVVLKGKWPS | 2101 | Q8TD26 | |
| TCPVLKGRVQKILHW | 501 | Q12873 | |
| PKVCGHRGNVLDVKW | 76 | Q92828 | |
| HVPSGRSEFKRCWKG | 16 | Q8NES8 | |
| VKHIRIPSCQDWKDI | 261 | Q5JW98 | |
| LKWKHCETPGVKTLC | 11 | Q5T5N4 | |
| NCLGAWVKLGSLKPH | 161 | Q9UPI3 | |
| AKEIVCKDGRWQSLP | 426 | Q9BXR6 | |
| CVKMTPTHKGQRWGL | 331 | O75165 | |
| TLRHKQAVCALKWSP | 351 | Q86Y33 | |
| HVWECLRKGMKESPV | 291 | Q9UQ10 | |
| EGEPLALRCHAWKDK | 116 | P12314 | |
| SGEKTVVCKHWLRGL | 61 | O95639 | |
| AEKVTSLGKDWHRPC | 136 | P52943 | |
| HPSLWPDIISKCAKV | 501 | Q6SJ93 | |
| CEKWVDGIRQFKHLP | 206 | Q86WA6 | |
| CLTHLLEWGKQRKGL | 161 | Q5VWM4 | |
| APPCTEHIKWKGLLL | 6 | Q9UQ72 | |
| HWNKKDCVEVKGLLP | 436 | Q9NQ36 | |
| VIWKNCHKDVIPSER | 1766 | Q6ZTR5 | |
| GPRKAWHLVGTVCVL | 91 | Q6NUT3 | |
| PQWPCGKHKRVLIFA | 311 | Q9BTV7 | |
| TRKTCFWRHQKGKPD | 231 | Q8N5C7 | |
| KLPNHRAAKRLWKVC | 366 | Q9Y2J2 | |
| PCHLARVVKIGSLEW | 106 | Q9BV36 | |
| PRQHEKHWKELCGRI | 216 | Q8IXS8 | |
| KHWKELCGRIVLDPE | 221 | Q8IXS8 | |
| GHCQRLTPEWKKAAT | 56 | Q15084 | |
| TSKDLQKHGNIWVCP | 571 | Q2NL67 | |
| WGPNVQRLACIKKHL | 621 | Q92833 | |
| KKFLGHIKRPWGICV | 56 | Q12908 | |
| GENPCKKVHWASGRR | 16 | Q9NXH3 | |
| PDLHLWACSGKRKDQ | 801 | A8MW92 | |
| VKIWHEIRTNGPKKG | 361 | Q9H300 | |
| GREEKCVWKHGITPP | 211 | Q5H9L4 | |
| KKWESGHCLKDRNEP | 246 | Q6P1N9 | |
| LAVKCTLADIWPLGK | 596 | O60522 | |
| IDWTHVTDPLIGCKK | 141 | Q9UPR3 | |
| ICSDIRQKWPVKHIA | 106 | O96007 | |
| TKGCVDAWEPKVLRA | 241 | Q9HC36 | |
| KGLRKVACIGAWHPA | 246 | Q92901 | |
| HWADGTNIKKPIKCS | 96 | Q9H8S9 | |
| NHVHKVVKERLCPWL | 31 | Q14CZ7 | |
| LGLCKPKIVHSNWNI | 46 | Q9NYY8 | |
| PKTATVLCDGKWHTL | 2966 | P25391 | |
| ACPVKKSHWDVVRSI | 151 | O75343 | |
| KIFVNGCWVGIHKDP | 566 | P30876 | |
| GIWEPKKGDVLCSRH | 51 | Q8TBB0 | |
| KILSLCPEIKWHFIG | 81 | O94903 | |
| KTLLPLHCGSKREWI | 781 | Q13018 | |
| KQPLCQLWAEKHGAR | 56 | Q96BD0 | |
| GSVPHDTWLPKKCSL | 116 | P13385 | |
| GKSSHGCPIAKWVLR | 1476 | Q8NFU7 | |
| KDAGKKVVPCRHDWH | 221 | Q9UHD1 | |
| LTTWKVGLCKDRLHK | 271 | Q9NS75 | |
| CSKLNKWVIPELIGH | 41 | Q9P003 | |
| CLTHLLEWGKQRKGL | 161 | Q5VXH5 | |
| NILCLSWKGRVPKSE | 16 | Q9NRJ4 | |
| TCLEQGKEPWNIKRH | 86 | Q8IYN0 | |
| RGGKICLTDHFKPLW | 111 | Q9Y3C8 | |
| HLCILKAKLGRPVTW | 36 | Q96HI0 | |
| CVKVWDISHPGNKSP | 506 | Q04724 | |
| LSSWCLKKPGHVAEV | 161 | Q92574 | |
| DGDAKPWCHVLKNRR | 271 | P00750 | |
| KKPEWVILIGVCTHL | 206 | P47985 | |
| TWLKRHCDVLAVPVK | 271 | Q9NUD5 | |
| AIALARKTEGCTKWP | 56 | Q68D42 | |
| LHEAVPGVRGSWKKK | 186 | P98077 | |
| KIWIPGPGAILCSKH | 51 | Q9H5L6 | |
| KAVVVPWGSCHFLEK | 86 | Q8TCT8 | |
| SKPKELVKRWHALCR | 456 | X6R8R1 | |
| DCVKPAVGGLRVKWD | 66 | Q9NSY2 | |
| AEHLRKRDKLWGVCV | 816 | Q9NXF1 | |
| SEIGQWHLKPTICKQ | 956 | Q9GZR1 | |
| EKAPKHVGFSVLLCW | 121 | Q7Z5H5 | |
| EGKSSRGCPIAKWVI | 881 | O43151 | |
| CIWKSHPSLCRKLGS | 246 | P36941 | |
| HPKKGCKWTLQRFRQ | 266 | Q3SXZ7 | |
| CLKGPKLSEIGTIAW | 291 | Q9C0K1 | |
| APPCTEHIKWKGLLV | 6 | P11465 | |
| DVKCVDWHPTKGLVV | 246 | Q9C0J8 | |
| EKVGKDTWLPRSHTC | 876 | Q9H0M0 | |
| AWINPKEGCKVHVVF | 91 | P49788 | |
| KLCLHKRDFIPGKWI | 671 | O60603 | |
| GSVPHDTWLPKKCSL | 116 | P51864 | |
| WDVKTGKCLKTLPAH | 156 | P61964 | |
| WECHKIRKQHKIPGG | 156 | A8MT65 | |
| IKKIIECVSVHPHWK | 291 | O43156 | |
| ALKADCGPQHRSGWK | 931 | P29597 | |
| LCFIPWIHSKKQREI | 466 | Q8TF71 | |
| KENVKLHCSIAGWPE | 291 | P52179 | |
| AKDWKTVPERFHCVG | 456 | P16519 |